These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 36791167)
1. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Chang LL; Allegretti J; Skinner AM; Dubberke ER N Engl J Med; 2023 Feb; 388(7):654-656. PubMed ID: 36791167 [No Abstract] [Full Text] [Related]
2. Does Prophylaxis Prevent Recurrent Berger RE NEJM Evid; 2022 Apr; 1(4):EVIDtt2200026. PubMed ID: 38319213 [TBL] [Abstract][Full Text] [Related]
3. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection. Brown CC; Manis MM; Bohm NM; Curry SR Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability? Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970 [TBL] [Abstract][Full Text] [Related]
5. Oral vancomycin prophylaxis against recurrent Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Johnson SW; Brown SV; Priest DH Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents. Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333 [TBL] [Abstract][Full Text] [Related]
8. Using oral vancomycin prescriptions as a proxy measure for Clostridium difficile infections: a spatial and time series analysis. Polgreen PM; Yang M; Kuntz JL; Laxminarayan R; Cavanaugh JE Infect Control Hosp Epidemiol; 2011 Jul; 32(7):723-6. PubMed ID: 21666407 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Knight EM; Schiller DS; Fulman MK; Rastogi R J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479 [TBL] [Abstract][Full Text] [Related]
12. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Collins DA; Riley TV Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124 [TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741 [TBL] [Abstract][Full Text] [Related]
14. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500 [TBL] [Abstract][Full Text] [Related]
15. Oral Vancomycin Prophylaxis for Clostridioides difficile in High-Risk Patients Receiving Systemic Antibiotics: What Exactly Are We Preventing? McCreery R; Cawcutt K; Cortes-Penfield N; Van Schooneveld T Clin Infect Dis; 2020 Oct; 71(7):1798. PubMed ID: 32052036 [No Abstract] [Full Text] [Related]
16. Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients. Lam AY; Gutin LS; Nguyen Y; Velayos FS Dig Dis Sci; 2020 Nov; 65(11):3111-3115. PubMed ID: 32749638 [No Abstract] [Full Text] [Related]
17. Oral Vancomycin as Secondary Prophylaxis for Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867 [TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862 [TBL] [Abstract][Full Text] [Related]
19. Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence. Zar FA Ann Intern Med; 2016 Jul; 165(2):JC4. PubMed ID: 27429316 [No Abstract] [Full Text] [Related]
20. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. Li Y; Figler RA; Kolling G; Bracken TC; Rieger J; Stevenson RW; Linden J; Guerrant RL; Warren CA BMC Infect Dis; 2012 Dec; 12():342. PubMed ID: 23217055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]